Article content

Clients sit in recliners watching videos or working on their laptops as rich, yellow plasma extracted from the bodies of the young drips into their veins.

The treatment doesn’t require any special preparation. It only takes about two hours to infuse two litres of plasma, the liquid element in the blood that normally holds red and white blood cells and platelets in the blood in suspension. It’s mostly painless, except maybe the bill. The cost to take part in treatments like this, part of a clinical trial run by a company called Ambrosia, is US$8,000 a pop.

We apologize, but this video has failed to load.

tap here to see other videos from our team. Try refreshing your browser, or This anti-aging startup says US$8,000 worth of young blood can help you live longer Back to video

But then, amortized over time even that’s a small price to pay for the hoped for results — the reversal of aging. The plasma flowing from IVs is from donors aged 16 to 25, the dream that it might rejuvenate the sluggish, shrinking cells of older clients.

According to company founder, Jesse Karmazin, transfusions are already bestowing Methuselah-like effects: One sixtysomething’s greying hair turned noticeably darker; a 55-year-old with early-onset Alzheimer’s showed improvements after just one treatment.